Nascent Biotech OTC Stock Executives
| NBIO Stock | USD 0.05 0.0004 0.73% |
Nascent Biotech employs about 5 people. The company is managed by 4 executives with a total tenure of roughly 20 years, averaging almost 5.0 years of service per executive, having 1.25 employees per reported executive. Analysis of Nascent Biotech's management performance can provide insight into the firm performance.
| Mark Glassy Chairman Chief Science Officer and Chairman of Scientific Advisory Board |
| Sean Carrick President President, Secretary and Director |
Nascent |
Nascent Biotech Management Team Effectiveness
The company has return on total asset (ROA) of (0.885) % which means that it has lost $0.885 on every $100 spent on assets. This is way below average. Nascent Biotech's management efficiency ratios could be used to measure how well Nascent Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Nascent Biotech Workforce Comparison
Nascent Biotech is considered to be number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is now estimated at about 26,458. Nascent Biotech adds roughly 5.0 in number of employees claiming only tiny portion of stocks in Biotechnology industry.
The company has Profit Margin (PM) of (1.25) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.92) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.92. Nascent Biotech Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Nascent Biotech Price Series Summation is a cross summation of Nascent Biotech price series and its benchmark/peer.
Nascent Biotech Notable Stakeholders
A Nascent Biotech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Nascent Biotech often face trade-offs trying to please all of them. Nascent Biotech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Nascent Biotech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Mark Glassy | Chief Science Officer and Chairman of Scientific Advisory Board | Profile | |
| Sean Carrick | President, Secretary and Director | Profile | |
| Lowell Holden | CFO, Chief Accounting Officer and Director | Profile | |
| Navpaul MD | Chief Consultant | Profile |
About Nascent Biotech Management Performance
The success or failure of an entity such as Nascent Biotech often depends on how effective the management is. Nascent Biotech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Nascent management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Nascent management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. In addition, the company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. Nascent Biotech operates under Biotechnology classification in the United States and is traded on OTC Exchange.
The data published in Nascent Biotech's official financial statements typically reflect Nascent Biotech's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Nascent Biotech's quantitative information. For example, before you start analyzing numbers published by Nascent accountants, it's essential to understand Nascent Biotech's liquidity, profitability, and earnings quality within the context of the Healthcare space in which it operates.
Nascent Biotech Workforce Analysis
Traditionally, organizations such as Nascent Biotech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Nascent Biotech within its industry.Nascent Biotech Manpower Efficiency
Return on Nascent Biotech Manpower
| Revenue Per Employee | 200K | |
| Revenue Per Executive | 250K | |
| Net Loss Per Employee | 94.1K | |
| Net Loss Per Executive | 117.6K | |
| Working Capital Per Employee | 76.6K | |
| Working Capital Per Executive | 95.8K |
Other Information on Investing in Nascent OTC Stock
Nascent Biotech financial ratios help investors to determine whether Nascent OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nascent with respect to the benefits of owning Nascent Biotech security.